磷脂酰肌醇蛋白多糖-3介导的信号通路与肝癌靶向治疗

陈洁; 姚敏; 姚登福

磷脂酰肌醇蛋白多糖-3介导的信号通路与肝癌靶向治疗

南通大学附属医院临床医学研究中心

基金项目:

江苏省卫生科技项目(H2009025)；南通市社会事业创新与示范计划项目(HS2011012)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 3371
- HTML全文浏览量: 17
- PDF下载量: 711
- 被引次数: 0
出版历程
- 出版日期: 2013-01-20

Role of glypican-3 signaling pathways and therapeutic potential in hepatocellular carcinoma

Research funding:

摘要

摘要:
磷脂酰肌醇蛋白多糖（GPC）-3相关信号通路与肝细胞癌（HCC）发生发展密切相关。GPC-3除用于HCC特异诊断外,靶向GPC-3可明显抑制HCC细胞增殖并诱导凋亡,有望成为HCC的分子靶目标。
- 肝肿瘤 /
- 醇类
Abstract:
Glypican-3 (GPC-3) signaling pathways contribute to the development and progression of hepatocellular carcinoma (HCC) .As a specific diagnostic marker of HCC, GPC-3 may also represent a novel therapeutic target.Recent studies have shown that molecular targeting of GPC-3 can significantly inhibit growth of HCC cells, as well as enhance apoptosis.Here, we discuss the underlying mechanisms of the GPC-3-mediated anti-proliferative and pro-apoptotic effects in HCC, which may help in development of improved GPC-3 targeted therapy.
- liver neoplasms /
- phosphatidylinositols

HTML全文

参考文献(46)

[1]Chiappini F.Circulating tumor cells measurements in hepato-cellular carcinoma[J].Int J Hepatol, 2012, 2012 (684802) :1-18.

[2]张海健, 姚登福, 秦呈林.膜联蛋白A2过表达在肝细胞癌发生发展中的作用[J].临床肝胆病杂志, 2011, 27 (7) :772-778.

[3]Lencioni R.Chemoembolization for hepatocellular carcinoma[J].Semin Oncol, 2012, 39 (4) :503-509.

[4]Fico A, Maina F, Dono R.Fine-tuning of cell signaling byglypicans[J].Cell Mol Life Sci, 2011, 68 (6) :923-929.

[5]Lai JP, Oseini AM, Moser CD, et al.The oncogenic effectof sulfatase 2 in human hepatocellular carcinoma is mediatedin part by glypican3-dependent Wnt activation[J].Hepa-tology, 2010, 52 (5) :1680-1689.

[6]Zittermann SI, Capurro MI, Shi W, et al.Soluble glypican 3inhibits the growth of hepato-cellular carcinoma in vitro andin vivo[J].Int J Cancer, 2010, 126 (6) :1291-1301.

[7]Gao W, Ho M.The role of glypican-3 in regulating Wnt inhepatocellular carcinomas[J].Cancer Rep, 2011, 1 (1) :14-19.

[8]Qian J, Yao D, Dong Z, et al.Characteristics of hepatic igf-ii expression and monitored levels of circulating igf-ii mRNAin metastasis of hepatocellular carcinoma[J].Am J ClinPathol, 2010, 134 (5) :799-806.

[9] Zhao H, Desai V, Wang J, et al.Epithelial-mesenchymaltransition predicts sensitivity to the dual IGF-1R/IR inhibitorOSI-906 in hepatocellular carcinoma cell lines[J].MolCancer Ther, 2012, 11 (2) :503-513.

[10]Cheng W, Tseng CJ, Lin TT, et al.Glypican-3-mediated on-cogenesis involves the insulin-like growth factor-signalingpathway[J].Carcinogenesis, 2008, 29 (7) :1319-1326.

[11]Lu JT, Zhao WD, He W, et al.Hedgehog signaling pathwaymediates invasion and metastasis of hepatocellular carcinomavia ERK pathway[J].Acta Pharmacol Sin, 2012, 33 (5) :691-700.

[12]Philips GM, Chan IS, Swiderska M, et al.Hedgehog signa-ling antagonist promotes regression of both liver fibrosis andhepatocellular carcinoma in a murine model of primary livercancer[J].PLoS One, 2011, 6 (9) :e23943.

[13]Li F, Shi W, Capurro M, et al.Glypican-5 stimulates rhab-domyosarcoma cell proliferation by activating Hedgehog sig-naling[J].J Cell Biol, 2011, 192 (4) :691-704.

[14]Ikushima H, Miyazono K.TGFbeta signalling:a complex web incancer progression[J].Nat Rev Cancer, 2010, 10 (6) :415-424.

[15]Sun CK, Chua MS, He J, et al.Suppression of glypican 3 inhib-its growth of hepatocellular carcinoma cells through up-regula-tion of TGF-β2[J].Neoplasia, 2011, 13 (8) :735-747.

[16]Yamazaki K, Masugi Y, Sakamoto M.Molecular pathogene-sis of hepatocellular carcinoma:altering transforming growthfactor-βsignaling in hepatocarcino-genesis[J].Dig Dis, 2011, 29 (3) :284-288.

[17]Boswell S, Sharif S, Alisa A, et al.Induction of latency-as-sociated peptide (transforming growth factor-β (1) ) ex-pression on CD4+T cells reduces Toll-like receptor 4 ligand-induced tumour necrosis factor-αproduction in a transfor-ming growth factor-β-dependent manner[J].Immunolo-gy, 2011, 133 (3) :278-287.

[18] Murakami Masuda Y, Wang X, Yokose S, et al.Effect ofglypican-1 gene on the pulp cells during the reparative den-tine process[J].Cell Biol Int, 2010, 34 (11) :1069-1074.

[19]Han X, Yan DM, Zhao XF, et al.GHGKHKNK octapeptide (P-5m) inhibits metastasis of HCCLM3 cell lines via regula-tion of MMP-2 expression in in vitro and in vivo studies[J].Molecules.2012, 17 (2) :1357-1372.

[20]Pan TL, Wang PW, Huang CC, et al.Network analysis andproteomic identification of vimentin as a key regulator associ-ated with invasion and metastasis in human hepatocellularcarcinoma cells[J].J Proteomics, 2012, 75 (15) :4676-4692.

[21]Yeh CB, Hsieh MJ, Hsieh YH, et al.Antimetastatic effectsof norcantharidin on hepato-cellular carcinoma by transcrip-tional inhibition of MMP-9 through modulation of NF-kBactivity[J].PLoS One, 2012, 7 (2) :e31055.

[22]Shirakawa H, Suzuki H, Shimomura M, et al.Glypican-3expression is correlated with poor prognosis in hepatocellularcarcinoma[J].Cancer Sci, 2009, 100 (8) :1403-1407.

[23]Suzuki M, Sugimoto K, Tanaka J, et al.Up-regulation ofglypican-3 in human hepatocellular carcinoma[J].Antican-cer Res, 2010, 30 (12) :5055-5061.

[24]Yao M, Yao DF, Bian YZ, et al.Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellularcarcinoma[J].Hepatobiliary Pancreat Dis Int, 2011, 10 (3) :289-294.

[25] Yasuda E, Kumada T, Toyoda H, et al.Evaluation for clinicalutility of GPC3, measured by a commercially available ELISAkit with Glypican-3 (GPC3) antibody, as a serological andhistological marker for hepatocellular carcinoma[J].HepatolRes, 2010, 40 (5) :477-485.

[26] 卞银珠, 姚登福, 张崇国, 等.磷脂酰肌醇蛋白多糖-3表达特征及对肝癌诊断与鉴别的临床价值[J].中华肝脏病杂志, 2011, 19 (4) :260-265.

[27] Yan D, He Q, Chen Y, et al.Detection ofα-fetoproteinand glypican-3 mRNAs in the peripheral blood of hepatocel-lular carcinoma patients by using multiple FQ-RT-PCR[J].J Clin Lab Anal, 2011, 25 (2) :113-117.

[28]姚敏, 杨燕, 姚登福, 等.循环血单核细胞GPC-3mRNA和AFP对肝癌诊断与转移监测的潜在价值[J].临床肝胆病杂志, 2012, 28 (10) :777-781.

[29]Tangkijvanich P, Chanmee T, Komtong S, et al.Diagnosticrole of serum glypican-3 in differentiating hepatocellular car-cinoma from non-malignant chronic liver disease and otherliver cancers[J].J Gastroenterol Hepatol, 2010, 25 (1) :129-137.

[30]Wang FH, Yip YC, Zhang M, et al.Diagnostic utility of glypi-can-3 for hepatocellular carcinoma on liver needle biopsy[J].J Clin Pathol, 2010, 63 (7) :599-603.

[31]Bruix J, Sherman M.American Association for the Study ofLiver Diseases.Management of hepatocellular carcinoma:anupdate[J].Hepatology, 2011, 53 (3) :1020-1022.

[32] Ning S, Bin C, Na H, et al.Glypican-3, a novel prognosticmarker of hepatocellular cancer, is related with postoperativemetastasis and recurrence in hepatocellular cancer patients[J].Mol Biol Rep, 2012, 39 (1) :351-357.

[33] Ho M, Kim H.Glypican-3:a new target for cancer immu-notherapy[J].Eur J Cancer, 2011, 47 (3) :333-338.

[34] Ho M.Advances in liver cancer antibody therapies:a focuson glypican-3 and mesothelin[J].BioDrugs, 2011, 25 (5) :275-284.

[35]Nakano K, Orita T, Nezu J, et al.Anti-glypican 3 antibodiescause ADCC against human hepatocellular carcinoma cells[J].Biochem Biophys Res Commun, 2009, 378 (2) :279-284.

[36]Takai H, Kato A, Kinoshita Y, et al.Histopathological analy-ses of the antitumor activity of antiglypican-3 antibody (GC33) in human liver cancer xenograft models:The contri-bution of macrophages[J].Cancer Biol Ther, 2009, 8 (10) :930-938.

[37]Nakano K, Ishiguro T, Konishi H, et al.Generation of a hu-manized anti-glypican 3 antibody by CDR grafting and stabil-ity optimization[J].Anticancer Drugs, 2010, 21 (10) :907-916.

[38]Allegretta M, Filmus J.Therapeutic potential of targeting glypi-can-3 in hepatocellular carcinoma[J].Anticancer Agents MedChem, 2011, 11 (6) :543-548.

[39] Feng M, Kim H, Phung Y, et al.Recombinant soluble glypi-can 3 protein inhibits the growth of hepatocellular carcinomain vitro[J].Int J Cancer, 2011, 128 (9) :2246-2247.

[40]Hu J, Dong A, Fernandez-Ruiz V, et al.Blockade of Wntsignaling inhibits angiogenesis and tumor growth in hepato-cellular carcinoma[J].Cancer Res, 2009, 69 (17) :6951-6959.

[41]Takahashi-Yanaga F, Kahn M.Targeting Wnt signaling:canwe safely eradicate cancer stem cells[J].Clin Cancer Res, 2010, 16 (12) :3153-3162.

[42] Mamiya T, Yamazaki K, Masugi Y, et al.Reduced transfor-ming growth factor-receptor II expression in hepatocellularcarcinoma correlates with intrahepatic metastasis[J].LabInvest, 2010, 90 (9) :1339-1345.

[43]Huynh H, Ngo VC, Koong HN, et al.AZD6244 enhances theanti-tumor activity of sorafenib in ectopic and orthotopicmodels of human hepatocellular carcinoma (HCC) [J].JHepatol, 2010, 52 (1) :79-87.

[44] Liu S, Li Y, Chen W, et al.Silencing glypican-3 expression in-duces apoptosis in human hepatocellular carcinoma cells[J].Biochem Biophys Res Commun, 2012, 419 (4) :656-661.

[45]Huang N, Lin J, Ruan J, et al.MiR-219-5p inhibits hepa-tocellular carcinoma cell proliferation by targeting glypican-3[J].FEBS Lett, 2012, 586 (6) :884-891.

[46]Ruan J, Liu F, Chen X, et al.Inhibition of glypican-3 expres-sion via RNA interference influences the growth and invasive a-bility of the MHCC97-H human hepatocellular carcinoma cellline[J].Int J Mol Med, 2011, 28 (4) :497-503.

施引文献

资源附件(0)

访问统计